Case Report
Mr KC, a 29-year-old African-American married man, has a 6-year history of apathy, low energy, anhedonia, sadness, hopelessness, insomnia, and increase in joint pain, leading to impairment in his performance of military duties, as well as in his relationship with his wife. Onset of symptoms occurred yearly, beginning in the fall and remitting in the spring. A detailed history revealed no symptoms of mania, psychosis, or anxiety. He has no history of alcohol and drug use. A family history revealed a biological mother suffering from major depression and a biological father suffering with alcoholism. Other than knee-joint pain, the patient has good physical health. He has been employed with the military for over 10 years. He presented to his physician at a military base with these symptoms and was diagnosed with major depression with seasonal pattern. Phototherapy treatment was unavailable at the military base. Further, because of duty shifts, it could not be offered as an option. A review of antidepressants provided evidence of a trial of selective serotonin reuptake inhibitors (SSRIs). Thus, a trial of citalopram 20 mg daily was initiated. At 2 and 4 weeks follow-up, Mr KC reported an increase in his energy level, an upbeat feeling, an improvement in mood, a restoration of normal sleep, and a significant decrease in knee-joint pain. His wife provided collateral information confirming this improvement. He started using less nonsteroidal antiinflammatory drug (NSAID) medication for pain and could return to some athletic activities, which he could not tolerate earlier.
Discussion
The DSM-IV states that the regular temporal relation between the onset of major depression in fall or winter and its full remission in spring characterizes seasonal patterns. In Alaska, a study estimated a prevalence of 9.2% for seasonal affective disorder (SAD) (1) . Light therapy has been the treatment of choice, with minimal side effects. Headache, eyestrain, and harmful effects on the retina are, however, potential side effects (2) . Data for the pharmacologic treatment of SAD are rather limited. In controlled trials, however, fluoxetine and propranolol have been effective. Open trials have also shown positive results with bupropion and monoamine oxidase inhibitors (3, 4) . One National Institute of Mental Health group has studied response to the serotonergic agent, m-cpp, in SAD patients, suggesting that serotonin dysregulation is an area for further study. One case study suggested that citalopram, an SSRI, was as effective as phototherapy for SAD. Because the neurobiology and the diagnostic validity of SAD is not always obvious, good history taking and a trial of antidepressants, such as citalopram, may prove to be an effective treatment option alone (5, 6) .
One major question that remains to be studied is whether patients with SAD should be weaned off antidepressants in the spring. If successful weaning off occurs, the same antidepressant medication may be as effective for the next likely episode. VK Dewan, MD, FRCPC James L Sullivan, MD Isha Dewan, Science Student Omaha, Nebraska
Factitious Anemia and Magnetic Resonance Imaging Abnormalities

Dear Editor:
Little is known about the causes and pathophysiology of factitious disorders. Several authors have proposed the possibility of preexisting organic cerebral lesions. Frontotemporal cerebral atrophy (1), marked hyperperfusion of the right hemithalamus (2), cerebral palsy (3), or areas of high signal in periventricular white matter in both hemispheres in T2-weighted magnetic resonance imaging (MRI) (4) have been respectively found in 4 patients who displayed Munchausen syndrome. We report a case of factitious anemia with MRI abnormalities, similar to those described by Fenelon and others (4).
Case Report
Ms O, a 35-year-old unmarried woman, was admitted to our psychiatric department after a suicide attempt. At psychiatric examination, Ms O did not fulfill DSM-IV criteria for any psychotic or affective disorder, and the suicide attempt rapidly appeared to be a response to perceived rejection. Throughout her hospitalization, Mrs O exhibited irritability, suggestibility, and poor insight.
A review of her medical record indicated a psychiatric history of factitious anemia that began at age 15 years and included many explorations and hospitalizations for 13 years. At age 28 years, she complained of transitory neurological symptoms, such as visual disturbances, paresthesia, and dizziness. Even so, the successive neurological examinations and complementary examinations (cerebrospinal fluid analysis, central visual field, and auditory, visual, and somatosensory-evoked potentials) were normal. The MRI of the brain, however, showed areas of high signal in periventricular white matter in both hemispheres in the T2-weighted sequence. These abnormalities, although not specific, first suggested the possibility of multiple sclerosis. Nevertheless, the normality of the different neurological examinations and the performed explorations did not favour this diagnosis.
Discussion
To our knowledge, this is the first report of MRI abnormalities in a patient with a factitious anemia. The first question raised is the link between the neurological symptoms and the MRI abnormalities. Although the diagnosis of multiple sclerosis cannot be invalidated, the absence of other objective neurological abnormalities does not support it. In this context, the subjective neurological complaints reported by the patient are consistent with the hypothesis of a neurological factitious disorder. The second remaining question is whether the MRI abnormalities that were found played a role in the development of factitious anemia.
This report raises an interesting question about cerebral lesions in the occurrence of pathomimia. To illuminate this association, we suggest further investigation to increase our understanding of the pathophysiology of factitious disorders.
Pregnancy and Respiratory Nocturnal Panic Attacks
Dear Editor:
Pregnancy may have a highly variable influence on the course of panic disorder (PD) (1) . Some case reports suggest that pregnancy protects against PD (2), but worsening or no change of PD during pregnancy is also reported (1).
We describe 2 women who were referred to the Laboratory of Panic and Respiration of the Federal University of Rio de Janeiro, with PD with prominent respiratory nocturnal panic attacks during pregnancy only.
Case Report 1
Mrs A, a 30-year-old white woman, started at age 26 years to have spontaneous diurnal attacks with palpitations, shortness of breath, choking, chest pain, dizziness, and fear of losing control. She was treated with imipramine (150 mg daily). After 18 months, she was asymptomatic and started to decrease the dosage. She had her first pregnancy after being free of psychotropic medications for 1 year. During the fourth month of pregnancy, however, she developed recurrent panic attacks during sleep. Her nocturnal panic attacks were intense and occurred almost nightly, with prominent respiratory symptoms (shortness of breath, chest pain, tingling, fear of dying and losing control, and severe choking). She never experienced nocturnal panic attacks before her pregnancy. She developed agoraphobic behaviour; she could only sleep seated, given her intense anticipatory anxiety at nightfall. She was initially treated with nortriptyline 10 mg daily. After 6 weeks, at the dosage of 75 mg daily, she achieved full remission of her respiratory nocturnal panic attacks. During her pregnancy, there was no diurnal panic attack. During the last 2 weeks of her pregnancy, nortriptyline was no longer prescribed. The asymptomatic period persisted after a 2-year follow-up.
Case Report 2
Mrs B, a 32-year-old white woman, began having diurnal panic attacks at age 22 years. During her panic attacks, the main symptoms were choking and shortness of breath. She was treated with paroxetine 20 mg daily. After 2 months, she no longer had panic attacks. For the next 32 months, she remained asymptomatic. During the fifth month of her second pregnancy, however, she started experiencing nocturnal panic attacks, with shortness of breath, chest pain, dyspnea, choking, paresthesias, sweating, tachycardia, and severe fear of dying. There was an intense anticipatory anxiety during sleep. She developed fear in falling asleep and performed her usual daily activities during the night. She was treated with nortriptyline and a dosage of 75 mg daily achieved complete remission. The drug was gradually discontinued during the last month of her pregnancy. At her 3-year follow-up, she had been without any panic attacks.
Discussion
The respiratory PD subtype appears as a distinct sample (3) . Nocturnal panic attacks are common, often neglected, and have been presenting with important respiratory symptoms. The physiology of
